198 related articles for article (PubMed ID: 21653319)
1. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.
Slupianek A; Dasgupta Y; Ren SY; Gurdek E; Donlin M; Nieborowska-Skorska M; Fleury F; Skorski T
Blood; 2011 Jul; 118(4):1062-8. PubMed ID: 21653319
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.
Slupianek A; Falinski R; Znojek P; Stoklosa T; Flis S; Doneddu V; Pytel D; Synowiec E; Blasiak J; Bellacosa A; Skorski T
Leukemia; 2013 Mar; 27(3):629-34. PubMed ID: 23047475
[TBL] [Abstract][Full Text] [Related]
3. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL stimulates WRN to promote survival and genomic instability.
Slupianek A; Poplawski T; Jozwiakowski SK; Cramer K; Pytel D; Stoczynska E; Nowicki MO; Blasiak J; Skorski T
Cancer Res; 2011 Feb; 71(3):842-51. PubMed ID: 21123451
[TBL] [Abstract][Full Text] [Related]
5. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
Zhu J; Zhou L; Wu G; Konig H; Lin X; Li G; Qiu XL; Chen CF; Hu CM; Goldblatt E; Bhatia R; Chamberlin AR; Chen PL; Lee WH
EMBO Mol Med; 2013 Mar; 5(3):353-65. PubMed ID: 23341130
[TBL] [Abstract][Full Text] [Related]
6. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
7. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
Cramer K; Nieborowska-Skorska M; Koptyra M; Slupianek A; Penserga ET; Eaves CJ; Aulitzky W; Skorski T
Cancer Res; 2008 Sep; 68(17):6884-8. PubMed ID: 18757400
[TBL] [Abstract][Full Text] [Related]
8. Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.
Singh MM; Howard A; Irwin ME; Gao Y; Lu X; Multani A; Chandra J
PLoS One; 2012; 7(12):e51611. PubMed ID: 23284724
[TBL] [Abstract][Full Text] [Related]
9. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS
Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898
[TBL] [Abstract][Full Text] [Related]
10. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1
Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P
Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.
Podszywalow-Bartnicka P; Wolczyk M; Kusio-Kobialka M; Wolanin K; Skowronek K; Nieborowska-Skorska M; Dasgupta Y; Skorski T; Piwocka K
Cell Cycle; 2014; 13(23):3727-41. PubMed ID: 25483082
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
13. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia.
Sun WT; Xiang W; Ng BL; Asari K; Bunte RM; Casey PJ; Wang M; Chuah C
Exp Hematol; 2016 Mar; 44(3):189-93.e2. PubMed ID: 26706195
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
[TBL] [Abstract][Full Text] [Related]
16. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
17. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
18. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
19. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH
Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378
[TBL] [Abstract][Full Text] [Related]
20. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
